Pharmaceutical Firm Prolius Medicine Submits Listing Application to Hong Kong Exchange

Stock News02-13 20:16

Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the prospectus, Prolius Medicine is a leading innovative antimicrobial peptide (AMP) therapeutics company established in April 2009. It focuses on four core therapeutic areas—anti-infectives, metabolic diseases, oncology, and autoimmune diseases—and aims to address significant unmet global health needs through its proprietary breakthrough technologies and drug candidates. As of the latest practicable date, the company has nine drug candidates, including one core product (PL-5) and two key products (PL-3301 and PL-18).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171533874?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171533874","market":"nz","top_or_hot":-1,"title":"Pharmaceutical Firm Prolius Medicine Submits Listing Application to Hong Kong Exchange","media":"Stock News","content":"<p>Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the prospectus, Prolius Medicine is a leading innovative antimicrobial peptide (AMP) therapeutics company established in April 2009. It focuses on four core therapeutic areas—anti-infectives, metabolic diseases, oncology, and autoimmune diseases—and aims to address significant unmet global health needs through its proprietary breakthrough technologies and drug candidates. As of the latest practicable date, the company has nine drug candidates, including one core product (PL-5) and two key products (PL-3301 and PL-18).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaceutical Firm Prolius Medicine Submits Listing Application to Hong Kong Exchange</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaceutical Firm Prolius Medicine Submits Listing Application to Hong Kong Exchange\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-13 20:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the prospectus, Prolius Medicine is a leading innovative antimicrobial peptide (AMP) therapeutics company established in April 2009. It focuses on four core therapeutic areas—anti-infectives, metabolic diseases, oncology, and autoimmune diseases—and aims to address significant unmet global health needs through its proprietary breakthrough technologies and drug candidates. As of the latest practicable date, the company has nine drug candidates, including one core product (PL-5) and two key products (PL-3301 and PL-18).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1171533874","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171533874","pubTimestamp":1770984975,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B"},"translate_title":"药企Prolius Medicine向港交所提交上市申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"HEXmain":1,"09939":1},"content_text":"Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the prospectus, Prolius Medicine is a leading innovative antimicrobial peptide (AMP) therapeutics company established in April 2009. It focuses on four core therapeutic areas—anti-infectives, metabolic diseases, oncology, and autoimmune diseases—and aims to address significant unmet global health needs through its proprietary breakthrough technologies and drug candidates. As of the latest practicable date, the company has nine drug candidates, including one core product (PL-5) and two key products (PL-3301 and PL-18).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171533874","isCrawlerRequest":true}